3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Neuroendocrine Tumors
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
4
Triple Negative Breast Neoplasms
3
Adenoma, Islet Cell
3
Recurrence
2
Meningioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Carcinoma, Hepatocellular
2
Carcinoid Tumor
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Thymus Neoplasms
1
Sarcoma
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Lymphangioleiomyomatosis
1
Locally Advanced Thyroid Gland Carcinoma
1
Kidney Neoplasms
1
HR+/HER2- Advanced Breast Cancer
1
Glioma
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Fulvestrant
4
trastuzumab deruxtecan
2
elacestrant
2
Vinorelbine
2
AZD9833
2
toripalimab
1
talazoparib
1
ribociclib
1
pyrotinib
1
palbociclib
1
olaparib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
apatinib
1
abemaciclib
1
Selective Estrogen Receptor Modulators
1
Radiotherapy
1
RAD1901
1
Letrozole
1
Injections
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Capecitabine
1
Aromatase Inhibitors
1
Anastrozole
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Advanced Breast Cancer
×
Everolimus
×
Clear all
NCT06382948
2026-04-03
ADELA
MedSIR
Phase 3
Recruiting
240 enrolled